GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET SIZE WAS VALUED AT USD 643 MILLION IN 2021 AND IS EXPECTED TO REACH USD 990.16 MILLION BY 2027, GROWING AT A CAGR OF 7.44% DURING 2021-2027

The Graft Versus Host Disease (GVHD) Treatment Market Size, Share, & Trends Analysis Report by

  • Drug Class: Corticosteroids, Kinase Inhibitors, Calcineurin Inhibitors, TNF-Alpha Inhibitors, and Other Class of Drugs
  • Treatment Type: GVHD Prophylaxis, Chronic GVHD, and Acute GVHD
  • Gender Type: Males and Females
  • Geography: North America, Europe, and APAC

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2022–2027.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

190 Pages

icon-table

6 Tables

icon-chart

134 Charts

icon-region

3 Regions

icon-country

8 Countries

icon-company

25 Companies

icon-market

5 Market Segment

GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 990 Million
Market Size (2021) USD 643 MILLION
CAGR (2022-2027) 7.44%
Base Year 2021
Forecast Year 2022-2027
Countries Covered US, France, Germany, Italy, UK, China, Japan and Spain
Geographic Analysis North America, Europe, APAC

MARKET OVERVIEW

Graft Versus Host Disease (GVHD) treatment market was valued at USD 643 million in 2021 and is expected to reach USD 990 million by 2027, growing at a CAGR of 7.44%.

GVHD is a condition that occurs when immune cells (T-cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells).

According to the estimates, the highest number of HSCTs is accessed in the United States, followed by China and Germany in 2020. The demand for Allo-HSCT is increasing faster. The trend is likely to continue during the forecast period due to the rising incidence of leukemia and lymphoma, rise in success rates of transplantation, and increase in the aging population.

Market Dynamics:

  • Launch of new therapies
  • Increase in Target Population with Allo-HSCT

Opportunities:

  • High Investment in R&D Activities
  • Novel Therapeutics inhibiting T-cell Proliferation and Activation

SEGMENTATION ANALYSIS

Corticosteroids drugs are expected to account for a significant share of the global graft versus host disease (GVHD) treatment market. However, the kinase inhibitors are expected to be the fastest-growing segment during the forecast period. Physicians recommend corticosteroids as a front-line therapy due to their proven safety and efficacy. In addition, the alternative drugs have less proven safety and efficacy, driving the physicians to recommend the corticosteroids only in front-line therapy. 

The acute GVHD (aGVHD) is expected to account for a significant share of the global graft versus host disease (GVHD) treatment market. For instance, a research study published by the National Center of Biotechnology Information in 2020 suggests that around 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.

Gender type: Among the gender type, males are expected to dominate the market. However, females are expected to be the fastest-growing segment during the forecast period. In males, a rise in hematopoietic stem cell transplantations is projected to augment the segment during the forecast period.

GEOGRAPHIC ANALYSIS

The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

VENDOR ANALYSIS

The GVHD treatment market is dominated by many companies offering generic and off-label drugs and selective pharma/biotech companies offering patented/commercial drugs for treating GVHD. The companies offering patented drugs for GVHD include Kadmon, Incyte Corp, Pharmacyclics, Bristol Myers Squibb, and Mesoblast. With more than 135 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

The Report Covers The following details:

  • Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
  • Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 – 2027 period
  • Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
  • Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 – 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

Frequently Asked Questions

WHAT WILL BE THE SIZE OF THE GVHD MARKET BY 2027?

The graft versus host disease market is expected to reach USD 990.16 million by 2027, growing at a CAGR of 7.44% during 2021-2027

WHAT ARE THE OPPORTUNITIES FOR VENDORS IN THE GRAFT VERSUS HOST DISEASE MARKET?

High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.

WHO ARE THE KEY PLAYERS IN THE GRAFT VERSUS HOST DISEASE TREATMENT MARKET?

Key vendors include Incyte, Pharmacyclics, Bristol-Myers Squibb, JCR Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Co Ltd (Takeda), and MaaT Pharma.

WHAT ARE THE FUTURE PROJECTION FOR THE TREATMENT OF THE GVHD MARKET?

In the next years, new monoclonal antibodies and inhibitors of critical costimulatory molecules will increase the therapeutic strategies for the prevention or treatment of patients with acute GVHD.

Download Free Sample

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

The following factors are likely to contribute to the growth of the market during the forecast period:

  • Rising Prevalence of GVHD across the World
  • Adaptation of Advanced Technologies
  • Increase in Incidence of Chronic GVHD Cases

Base Year: 2021

Forecast Year: 2022-2027

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

Key Players

  • Incyte
  • Pharmacyclics
  • Bristol-Myers Squibb
  • JCR Pharmaceuticals Co., Ltd.
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • MaaT Pharma
  • XeniKos
  • Medac GmbH
  • Mesoblast
  • Kadmon
  • Jazz Pharmaceuticals
  • Gsk
  • Novartis
  • Syndax Pharmaceuticals Inc

Other Prominent Vendors

  • Neovii
  • ElsaLys Biotech
  • Mallinckrodt
  • Regimmune
  • Roche
  • Altrubio
  • CTTQ
  • Equillium
  • Janssen (johnson & johnson)
  • ASC Therapeutics
  • MSD
  • Genentech
  • Sun Pharma
  • Mink Therapeutics
  • Pluristem

Market Segmentation by Drug Class

  • Corticosteroids
  • Kinase Inhibitors
  • Calcineurin Inhibitors
  • TNF-Alpha Inhibitors
  • Other Class of Drugs

Market Segmentation by Treatment Type

  • GVHD Prophylaxis
  • Chronic GVHD
  • Acute GVHD

Market Segmentation by Gender Type

  • Males
  • Females

Market Segmentation by Geography

  • North America
    • US
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
  • APAC
    • China
    • Japan

CHAPTER – 1: GVHD OVERVIEW

  • Graft Versus Host Disease – An Overview

CHAPTER – 2: GVHD EPIDEMIOLOGY & OVERVIEW

  • 8MM: Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • 8MM: Comparative Analysis of HSCT & Allogeneic – HSCT
  • 8MM: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • 8MM: Comparative Analysis of incidence of aGVHD & cGVHD
  • US: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • US: Comparative Analysis of HSCT & Allogeneic – HSCT
  • US: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • US: Comparative Analysis of incidence of aGVHD & cGVHD
  • China: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • China: Comparative Analysis of HSCT & Allogeneic – HSCT
  • China: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • China: Comparative Analysis of incidence of aGVHD & cGVHD
  • Germany: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • Germany: Comparative Analysis of HSCT & Allogeneic – HSCT
  • Germany: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Germany: Comparative Analysis of incidence of aGVHD & cGVHD
  • Japan: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • Japan: Comparative Analysis of HSCT & Allogeneic – HSCT
  • Japan: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Japan: Comparative Analysis of incidence of aGVHD & cGVHD
  • France: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • France: Comparative Analysis of HSCT & Allogeneic – HSCT
  • France: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • France: Comparative Analysis of incidence of aGVHD & cGVHD
  • Italy: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • Italy: Comparative Analysis of HSCT & Allogeneic – HSCT
  • Italy: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Italy: Comparative Analysis of incidence of aGVHD & cGVHD
  • UK: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • UK: Comparative Analysis of HSCT & Allogeneic – HSCT
  • UK: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • UK: Comparative Analysis of incidence of aGVHD & cGVHD
  • Spain: Historic & Projected Volume of HSCT & Allogeneic – HSCT
  • Spain: Comparative Analysis of HSCT & Allogeneic – HSCT
  • Spain: Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Spain: Comparative Analysis of incidence of aGVHD & cGVHD

CHAPTER – 3: GVHD MARKET SIZE & OVERVIEW

  • 8MM: Historic & Projected Revenue of GVHD
  • 8MM: Historic & Projected Revenue of GVHD Snapshot
  • 8MM: Major Approved & Off-label Drugs in GVHD
  • 8MM: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • US: Historic & Projected Revenue of GVHD
  • US: Historic & Projected Revenue of GVHD Snapshot
  • US: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • China: Historic & Projected Revenue of GVHD
  • China: Historic & Projected Revenue of GVHD Snapshot
  • China: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Germany: Historic & Projected Revenue of GVHD
  • Germany: Historic & Projected Revenue of GVHD Snapshot
  • Germany: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Japan: Historic & Projected Revenue of GVHD
  • Japan: Historic & Projected Revenue of GVHD Snapshot
  • Japan: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • France: Historic & Projected Revenue of GVHD
  • France: Historic & Projected Revenue of GVHD Snapshot
  • France: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Italy: Historic & Projected Revenue of GVHD
  • Italy: Historic & Projected Revenue of GVHD Snapshot
  • Italy: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • UK: Historic & Projected Revenue of GVHD
  • UK: Historic & Projected Revenue of GVHD Snapshot
  • UK: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Spain: Historic & Projected Revenue of GVHD
  • Spain: Historic & Projected Revenue of GVHD Snapshot
  • Spain: Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class

CHAPTER – 4: GVHD MARKETED DRUGS OVERVIEW

  • GVHD Marketed Drugs – An Overview
  • GVHD Marketed Drugs – Summary

CHAPTER – 5: GVHD PIPELINE DRUGS OVERVIEW

  • GVHD Pipeline Drugs – An Overview
  • GVHD Pipeline Drugs – Snapshot
  • GVHD Pipeline Drugs Overview & Snapshot – By Disease type
  • GVHD Pipeline Drugs Overview & Snapshot – By Development Phase
  • GVHD Pipeline Drugs Overview & Snapshot – By Route of Administration
  • GVHD Pipeline Drugs Overview & Snapshot – By Mechanism of Action
  • GVHD Pipeline Drugs Overview & Snapshot – By Molecule type
  • GVHD Pipeline Drugs Overview & Snapshot – By Geography type

CHAPTER – 6: GVHD CLINICAL TRIALS OVERVIEW

  • GVHD Clinical Trials Overview Snapshot
  • GVHD Clinical Trials Overview – By Recruitment Status
  • GVHD Clinical Trials Overview – By Product type
  • GVHD Clinical Trials Overview – By Route of Administration
  • GVHD Clinical Trials Overview – By Molecule type
  • GVHD Clinical Trials Overview – By Geography type

CHAPTER – 7: GVHD MARKET DYNAMICS

  • GVHD Treatment Market Drivers
  • GVHD Treatment Market Constraints
  • GVHD Treatment Market Trends

CHAPTER – 8: GVHD COMPETITIVE LANDSCAPE

  • GVHD Competitive Landscape – Marketed Drugs
  • Unmet Needs & Strategic Recommendations
  • Competitive Assessment of Off-label & Late-stage Drugs
  • Key Company Profiles
  • Competitive Scenario of GVHD Treatment Market
  • Other Prominent Company Profiles
  • Key Company Overviews
  • GVHD Competitive Landscape – Pipeline Drugs
  • Key Emerging Company Profiles
  • Key Emerging Company Overviews
  • Other Prominent Company Profiles

CHAPTER – 9: GVHD MISCELLANEOUS

  • Key Tentative Drug Approvals Timeline
  • Key Regulatory Designations
  • Key Milestones
  • Deals & Collaborations
  • Inactive/Discontinued/Dormant Products

CHAPTER – 10: APPENDIX

  • About Arizton
  • Research Methodology
  • List of Abbreviations

LIST OF EXHIBITS

Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS

Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS

Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)

Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 – 2027)

Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS

 Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS

Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)

Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)

Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES

Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES

Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)

 Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)

Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES

Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES

Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)

Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)

Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA

 Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA

Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)

Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)

Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA

 Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA

Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)

Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)

Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY

 Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY

Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)

Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)

Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY

 Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY

Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)

Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)

Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN

Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN

Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)

Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)

Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN

 Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN

Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)

Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)

Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE

Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE

Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)

 Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)

Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE

 Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE

Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)

Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)

Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY

 Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY

Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)

Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)

Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY

 Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY

Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)

Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)

Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM

 Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM

Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)

Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)

Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM

 Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM

Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)

Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)

Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN

 Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN

Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)

Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)

Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN

 Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN

Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)

Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)

Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS

Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS

Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET

Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS

Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS

Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS

Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES

Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES

Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES

Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES

Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES

Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA

Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA

Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA

Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA

Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA

Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY

Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY

Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY

Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY

Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY

Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN

Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN

Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN

Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN

Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN

Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE

Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE

Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE

Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE

Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE

Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY

Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY

Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY

Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY

Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY

Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM

Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM

Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM

Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM

Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM

Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN

Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN

Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN

Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN

Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN

Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET

Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT

Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT

Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE

Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE

Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION

Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION

Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE

Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE

Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD

Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD

Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD

Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS

Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS

Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS

Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT

LIST OF TABLES

Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET

Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET

Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET

Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET

Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET

Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date